S&P 500
7,693.70
+27.10
+0.35%
Dow
53,318.19
+256.24
+0.48%
Nasdaq
26,380.74
+162.91
+0.62%
NYSE Composite
24,612.97
+117.42
+0.48%
Russell 2000
2,965.36
+12.19
+0.41%
VIX
15.04
-0.16
-1.05%
SMMT · Summit Therapeutics Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Summit Therapeutics Inc (SMMT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$16.02
+1.41
(+9.65%)
● Market open
DAY'S RANGE
$16.02
$15.54
$16.32
52-WEEK RANGE
$16.02
$12.07
$29.23
What's happening
- SMMT is up 9.65% today, trading at $16.02. — Live quote
- Volume today (160,334) is well below its 3-month average of 5,224,660. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $-0.28 actual vs. $-0.28 estimated (+1.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 11
Hold 8
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (24 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SMMT
-19.04%
vs S&P 500
-30.75%
1-YEAR RETURN
SMMT
-40.60%
vs S&P 500
-59.58%
6-MONTH RETURN
SMMT
-10.38%
3-MONTH RETURN
SMMT
-9.87%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.28
Est. $-0.28
BEAT +1.7%
2026-04-26 (Q1 2026)
$-0.24
Est. $-0.18
MISS -33.3%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.07
MISS -342.1%
2025-10-26 (Q3 2025)
$-0.31
Est. $-0.13
MISS -130.5%
Valuation Measures & Ratios
Enterprise Value4$10.92B
Forward P/E5—
PEG Ratio6-1.14
Price / Sales (TTM1)11808.36
Price / Book717.95
EV4 / Revenue11371.52
EV4 / EBITDA—
Profit Margin-9027.08%
Operating Margin-8108.33%
Return on Equity (ROE8)-168.93%
Return on Assets (ROA9)-141.92%
Avg Volume (3M)5,224,660
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $11.22B | $14.96B | $15.45B | $15.82B | $13.49B |
| P/E | -9.33 | -14.25 | -16.85 | -21.22 | -60.48 |
| Price/Book | 17.82 | 27.40 | 80.35 | 60.97 | 39.17 |
| ROE | -190.90% | -192.30% | -476.78% | -287.26% | -64.77% |
| ROA | -159.88% | -162.05% | -350.24% | -229.99% | -58.11% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short37,432,330
Change from Prior Settlement+3.27%
% of Float—
Days to Cover (Short Ratio)8.69
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-03; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -9027.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -40.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SMMT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | — | — |
| Operating income | — | — | — | — | — | -$58.4M | -$59.6M | -$42.4M |
| Net income | -$215.7M | -$189.4M | -$231.8M | -$565.7M | -$62.9M | -$56.3M | -$60.4M | -$43.5M |
| EPS (diluted) | $-0.28 | $-0.24 | $-0.31 | $-0.76 | $-0.09 | $-0.08 | $-0.09 | $-0.06 |
| EPS (basic) | $-0.28 | $-0.24 | $-0.31 | $-0.76 | $-0.09 | $-0.08 | $-0.09 | $-0.06 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $752.2M | $647.9M | $751.2M | $261.7M | $324.0M | $383.8M | $435.6M | $502.9M |
| Total liabilities | $122.2M | $101.9M | $92.3M | $69.5M | $64.6M | $39.5M | $46.8M | $64.9M |
| Stockholders' equity | $630.0M | $545.9M | $658.9M | $192.3M | $259.4M | $344.3M | $388.7M | $437.9M |
| Total current assets | $720.6M | $616.6M | $720.3M | $246.5M | $309.2M | $370.8M | $423.8M | $490.3M |
| Total current liabilities | $103.6M | $83.3M | $73.0M | $64.9M | $60.3M | $34.9M | $41.7M | $59.0M |
| Cash & equivalents | $419.4M | $106.5M | $225.3M | $238.6M | $297.9M | $211.5M | $104.9M | $93.8M |
| Marketable securities (current) | $271.3M | $492.2M | $488.2M | $0 | $0 | $149.8M | $307.5M | $393.1M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $1.8M | $1.7M | $1.1M | $810.0K | $690.0K | $652.0K | $254.0K | $265.0K |
| Goodwill | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $1.9M | $1.9M | $2.0M |
| Intangible assets | — | — | — | — | — | — | $0 | — |
| Other non-current assets | $8.4M | $8.2M | $7.2M | $7.0M | $6.5M | $4.1M | $2.5M | $1.9M |
| Accounts payable | $22.9M | $27.5M | $20.3M | $22.2M | $23.0M | $5.0M | $4.6M | $3.3M |
| Accrued liabilities | $65.1M | $44.3M | $32.1M | $27.0M | $26.1M | $21.2M | $19.6M | $18.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $2.6M | $1.1M | $2.3M | $2.0M | $1.5M | $759.0K | $1.8M | $1.0M |
| Other non-current liabilities | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.7M | $1.6M | $1.7M |
| Common stock & paid-in capital | $7.9M | $7.8M | $7.8M | $7.4M | $7.4M | $7.4M | $7.4M | $7.4M |
| Retained earnings | -$2.70B | -$2.48B | -$2.29B | -$2.07B | -$1.84B | -$1.28B | -$1.21B | -$1.15B |
| Accumulated other comprehensive income (loss) | -$2.7M | -$2.6M | -$2.5M | -$2.7M | -$2.8M | -$2.6M | -$2.3M | -$2.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$141.1M | -$122.3M | -$101.9M | -$93.1M | -$66.7M | -$61.2M | -$48.7M | -$30.3M |
| Investing cash flow | $222.9M | -$238.0K | -$485.2M | -$71.0K | $150.8M | $160.1M | $83.5M | -$108.6M |
| Financing cash flow | $231.1M | $3.8M | $573.8M | $33.8M | $2.2M | $7.7M | -$23.6M | $204.1M |
| Free cash flow | -$142.0M | -$122.5M | -$102.1M | -$93.2M | -$66.7M | -$61.6M | -$48.7M | -$30.4M |
| Capital expenditures | $909.0K | $245.0K | $164.0K | $71.0K | $0 | $422.0K | $14.0K | $58.0K |
| Share-based compensation | $68.7M | $72.8M | $111.8M | $130.8M | $478.8M | $11.1M | $11.0M | $19.4M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | $0 | $0 |
| Change in accounts payable | -$3.9M | $6.8M | -$2.1M | -$839.0K | $17.9M | $356.0K | $1.5M | -$181.0K |
| Dividends paid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $705.0K | $1.8M |
| Operating income | — | -$226.0M | -$609.6M | -$72.1M | -$86.2M |
| Net income | -$1.08B | -$221.3M | -$614.9M | -$78.8M | -$88.6M |
| EPS (diluted) | $-1.44 | $-0.31 | $-0.99 | $-0.41 | $-0.67 |
| EPS (basic) | $-1.44 | $-0.31 | $-0.99 | $-0.41 | $-0.67 |
| Operating margin | — | — | — | -$10.2K | -$4.8K |
| Net margin | — | — | — | -$11.2K | -$4.9K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $751.2M | $435.6M | $202.9M | $664.2M | $113.4M |
| Total liabilities | $92.3M | $46.8M | $125.3M | $537.5M | $30.1M |
| Stockholders' equity | $658.9M | $388.7M | $77.7M | $126.7M | $83.3M |
| Total current assets | $720.3M | $423.8M | $189.7M | $656.7M | $97.3M |
| Total current liabilities | $73.0M | $41.7M | $20.4M | $38.8M | $25.6M |
| Cash & equivalents | $225.3M | $104.9M | $71.4M | $348.6M | $71.8M |
| Marketable securities (current) | $488.2M | $307.5M | $114.8M | $0 | — |
| Accounts receivable | — | — | $0 | $349.0K | $1.5M |
| Other current assets | — | — | $181.0K | $486.0K | $1.2M |
| Property, plant & equipment | $1.1M | $254.0K | $204.0K | $906.0K | $694.0K |
| Goodwill | $2.0M | $1.9M | $1.9M | $1.8M | $2.0M |
| Intangible assets | — | $0 | $0 | — | — |
| Other non-current assets | $7.2M | $2.5M | $4.3M | $577.0K | $170.0K |
| Accounts payable | $20.3M | $4.6M | $2.7M | $355.0K | $4.4M |
| Accrued liabilities | $32.1M | $19.6M | $8.8M | $10.7M | $7.2M |
| Deferred revenue (current) | — | — | — | $0 | $7.9M |
| Other current liabilities | $2.3M | $1.8M | $717.0K | $662.0K | $897.0K |
| Other non-current liabilities | $1.8M | $1.6M | $1.6M | $1.4M | $2.8M |
| Common stock & paid-in capital | $7.8M | $7.4M | $7.0M | $2.1M | $980.0K |
| Retained earnings | -$2.29B | -$1.21B | -$993.3M | -$378.3M | -$299.5M |
| Accumulated other comprehensive income (loss) | -$2.5M | -$2.3M | -$2.4M | -$1.9M | -$2.2M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$322.9M | -$142.1M | -$76.8M | -$41.6M | -$72.6M |
| Investing cash flow | -$174.3M | -$205.3M | -$587.8M | -$624.0K | -$306.0K |
| Financing cash flow | $617.5M | $381.2M | $86.5M | $620.2M | $77.9M |
| Free cash flow | -$323.6M | -$142.2M | -$76.9M | -$42.2M | -$72.9M |
| Capital expenditures | $657.0K | $139.0K | $128.0K | $624.0K | $306.0K |
| Share-based compensation | $732.4M | $51.0M | $14.1M | $11.9M | $12.8M |
| Deferred income taxes | — | — | — | — | $0 |
| Change in accounts receivable | — | $0 | -$359.0K | -$975.0K | $1.1M |
| Change in accounts payable | $15.3M | $2.0M | $2.3M | -$4.1M | -$1.7M |
| Dividends paid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SMMT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers15.4%
Shares Outstanding778,184,568
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 32,786,348 | $477.7M | 4.21% | -9.9% | 2026-08-14 |
| FMR LLC | 10,043,947 | $146.3M | 1.29% | -7.5% | 2026-08-13 |
| State Street Corp | 9,536,796 | $139.0M | 1.23% | +35.7% | 2026-08-07 |
| BlackRock, Inc. | 9,529,041 | $138.8M | 1.22% | -1.3% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,734,484 | $83.6M | 0.74% | +0.4% | 2026-06-30 |
| UBS Group AG | 5,233,798 | $76.3M | 0.67% | +42.2% | 2026-08-13 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,042,190 | $73.5M | 0.65% | -3.7% | 2026-06-30 |
| Goldman Sachs Group Inc | 4,513,399 | $65.8M | 0.58% | +1352.5% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,893,820 | $56.7K | 0.50% | -53.0% | 2026-08-14 |
| Point72 Asset Management, L.P. | 3,697,803 | $53.9M | 0.48% | +371.5% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,427,263 | $50.0M | 0.44% | +3.4% | 2026-08-12 |
| MILLENNIUM MANAGEMENT LLC | 2,349,081 | $34.2M | 0.30% | +1760.3% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,989,591 | $29.0M | 0.26% | +0.0% | 2026-08-14 |
| BALYASNY ASSET MANAGEMENT L.P. | 1,904,254 | $27.7M | 0.24% | +247.3% | 2026-08-13 |
| CITADEL ADVISORS LLC | 1,725,716 | $25.1M | 0.22% | +290.7% | 2026-08-14 |
| Aberdeen Group plc | 1,693,626 | $24.7M | 0.22% | +154.5% | 2026-07-31 |
| Squarepoint Ops LLC | 1,590,736 | $23.2M | 0.20% | +159.1% | 2026-08-14 |
| Morgan Stanley | 1,450,019 | $21.1M | 0.19% | -12.2% | 2026-08-11 |
| NORGES BANK | 1,382,519 | $20.1M | 0.18% | +0.0% | 2026-08-12 |
| Logos Global Management LP | 1,350,000 | $19.7M | 0.17% | +0.0% | 2026-08-14 |
| Octagon Capital Advisors LP | 1,250,000 | $18.2M | 0.16% | +0.0% | 2026-08-14 |
| D. E. Shaw & Co., Inc. | 1,243,556 | $18.1M | 0.16% | -44.5% | 2026-08-14 |
| Kynam Capital Management, LP | 1,200,000 | $17.5M | 0.15% | +0.0% | 2026-08-14 |
| Pictet Asset Management Holding SA | 1,134,299 | $16.4M | 0.15% | -14.3% | 2026-07-30 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 976,851 | $14.2M | 0.13% | +1.7% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-30 to 2026-06-12
Recent transactions
- Insiders have net bought 7,870,000 shares over the last 182 days, across 6 purchases and 0 sales.
- Most recent: Zanganeh Mahkam (Co-Chief Executive Officer) — Open market purchase of 3,810,000 shares on 2026-06-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)7,870,000 sh(6 txns)
Sales (open market)0 sh(0 txns)
Net Shares+7,870,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer | Open market purchase | 2026-06-12 | 3,810,000 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | Open market purchase | 2026-06-12 | 3,810,000 |
| Soni Manmeet Singh | COO and CFO | Open market purchase | 2026-06-04 | 25,000 |
| Xia Yu | Director | Open market purchase | 2025-10-21 | 533,617 |
| Anand Bhaskar | Chief Accounting Officer | Grant / award | 2025-10-21 | 26,680 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-12 | Zanganeh Mahkam | Co-Chief Executive Officer | Open market purchase | 3,810,000 | $13.12 |
| 2026-06-12 | DUGGAN ROBERT W | Co-Chief Executive Officer | Open market purchase | 3,810,000 | $13.12 |
| 2026-06-04 | DUGGAN ROBERT W | Co-Chief Executive Officer | Open market purchase | 100,000 | $14.60 |
| 2026-06-04 | Zanganeh Mahkam | Co-Chief Executive Officer | Open market purchase | 100,000 | $14.60 |
| 2026-06-04 | Soni Manmeet Singh | COO and CFO | Open market purchase | 25,000 | $14.46 |
| 2026-06-04 | Soni Manmeet Singh | COO and CFO | Open market purchase | 25,000 | $14.43 |
| 2025-10-21 | Xia Yu | Director | Open market purchase | 533,617 | $18.74 |
| 2025-10-21 | Anand Bhaskar | Chief Accounting Officer | Grant / award | 26,680 | $18.74 |
| 2025-10-21 | Soni Manmeet Singh | COO and CFO | Grant / award | 53,361 | $18.74 |
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | Grant / award | 13,980,789 | $18.74 |
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | Grant / award | 266,808 | $18.74 |
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | Open market purchase | 26,680 | $18.74 |
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | Grant / award | 266,808 | $18.74 |
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | Open market purchase | 26,680 | $18.74 |
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | Grant / award | 13,980,789 | $18.74 |
| 2025-09-11 | Zanganeh Mahkam | Co-Chief Executive Officer | Open market purchase | 5,000 | $18.07 |
| 2025-09-11 | DUGGAN ROBERT W | Co-Chief Executive Officer | Open market purchase | 5,000 | $18.07 |
| 2025-09-10 | Zanganeh Mahkam | Co-Chief Executive Officer | Open market purchase | 333,394 | $17.68 |
| 2025-09-10 | DUGGAN ROBERT W | Co-Chief Executive Officer | Open market purchase | 333,394 | $17.68 |
| 2025-05-30 | Zanganeh Mahkam | Co-Chief Executive Officer | Option exercise | 74,545 | $2.64 |
| 2025-05-30 | DUGGAN ROBERT W | Co-Chief Executive Officer | Option exercise | 74,545 | $2.64 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 14:08 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-03 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-08-26 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-23 | 8-K | 2026-07-23 | View on SEC.gov → |
| 2026-07-23 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-23 | 8-K | 2026-07-23 | View on SEC.gov → |
| 2026-07-22 | 8-K | 2026-07-22 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-12 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-12 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-04 | View on SEC.gov → |
Recent news
Headlines about SMMT (Summit Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet
SeekingAlpha · 2026-09-03 -
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
Seeking Alpha · 2026-09-02 -
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Yahoo Finance · 2026-08-28 -
Summit Therapeutics (SMMT) Published Phase III HARMONi Results In The Lancet Oncology
Yahoo Finance · 2026-08-27 -
Summit Therapeutics (SMMT) Is Up 8.5% After New Phase III Biliary Cancer Data For Ivonescimab
Yahoo Finance · 2026-08-27 -
Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim
Yahoo Finance · 2026-08-26 -
Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)
SeekingAlpha · 2026-08-26 -
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
Benzinga · 2026-08-26
No headlines in this category right now — try “All”.